Dr. Estela Rodriguez· @Latinamd · X·· 12 hours agoScore70
Body · original
💯% agree Huge logistics and potential #GlobalOnc disparities for the deployment of a personalized adjuvant mRNA vaccine (intismeran autogene) INTerpath-001 trial
for melanoma presented today at #ESMO26
“Lack of access to new treatments 🟰 unfulfilled promise”
Maybe the market was reacting to this access challenge and not the magnitude of benefit❓#healthequity @GlopesMd
49 views · 1 like · 2 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSo the “not-so-official-anymore“ presentation is in: The melanoma vaccine works. We knew that, 82% recurrence-free at two years vs 70% with immunotherapy alone. It's built individually for each patient, the logistics are enormous: Sequence their tumor, design the vaccine, manufacture it for one person. Weeks of work that will cost a fortune. A treatment like that doesn't scale to most of the world. It scales to countries that can afford a factory run per patient. I live in a country which happens to be able to afford that, most countries can’t. Melanoma kills people everywhere. This will reach a fraction of them. Solving cancer and solving access are two different problems. We just got better at the first one.在 X 查看被引用的帖子
Source: Dr. Estela Rodriguez · x.com
